---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-019074"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:46:05.971160+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia

## Summary
- KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).
- ESS decreased ~9 points after 5 weeks; at week 7: ESS -9.4 (QD), -8.8 (BID); IHSS -16.1 QD, -12.3 BID.
- Sleep Inertia VAS decreased 25.9 (QD) and 17.2 (BID); Brain Fog Scale decreased 23.8 (QD) and 22.3 (BID).
- PK data supports nighttime dosing; European Commission granted Orphan Drug Designation for KP1077 in IH.

## SEC filing metadata
- accession: 0001437749-24-019074
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924019074/0001437749-24-019074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924019074/zvra20240530c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-019074
- JSON: https://secwatch.observer/filing/0001437749-24-019074.json
- Plain text: https://secwatch.observer/filing/0001437749-24-019074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.